Castle Biosciences, Inc. will present innovative research on cutaneous melanoma (CM) and uveal melanoma (UM) at the 2025 ASCO Annual Meeting in Chicago, showcasing findings from a collaboration with ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating the ...
New, combined validation cohort of 1,412 patients with high-risk squamous cell carcinoma (SCC) demonstrates that the addition of DecisionDx-SCC to Brigham & Women's Hospital (BWH) staging ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Hosted on MSN
Castle Biosciences, Inc. (CSTL) Unveils Largest Real-World Melanoma Risk Study at ASCO 2025
Castle Biosciences, Inc. (NASDAQ:CSTL) has announced new data to be presented at ASCO 2025 showing that its DecisionDx-Melanoma test is linked to a 32% reduction in mortality risk for patients with ...
Castle Biosciences will present TissueCypher Barrett’s Esophagus test data at DDW 2025, emphasizing risk stratification and personalized patient management. Castle Biosciences, Inc. will present new ...
DECIDE showed clinical utility: patients with low predicted nodal risk who avoided SLNB had a 97.8% three‑year recurrence‑free survival and low false‑negative rates (2.6% overall; 1.8% in T1/T2a), ...
Data from 1,868 Surveillance, Epidemiology and End Results (SEER)-linked patients show DecisionDx-Melanoma significantly stratifies five-year melanoma-specific survival within American Joint Committee ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results